Performance of relative enhancement on multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) from Papillary and Chromophobe RCC subtypes and oncocytoma

Jonathan R Young, Heidi Coy, Hyun J. Kim, Michael Douek, Pechin Lo, Allan J. Pantuck, Steven S. Raman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE. The objective of our study was to investigate the performance of relative enhancement on multiphasic MRI to differentiate clear cell renal cell carcinoma (RCC) from other RCC subtypes (papillary and chromophobe) and oncocytoma. MATERIALS AND METHODS. For this study, we derived a cohort of 34 clear cell RCCs, nine oncocytomas, 12 papillary RCCs, and 10 chromophobe RCCs with a preoperative multiphasic dynamic contrast-enhanced MRI study with up to four phases (i.e., unenhanced, corticomedullary, nephrographic, excretory) from 2005 to 2016. These groups were evaluated for multiphasic enhancement and were compared using Kruskal-Wallis and Mann-Whitney tests. ROC curves were constructed and logistic regression analyses were performed to evaluate the performance of multiphasic enhancement in differentiating clear cell RCCs from the other three groups. RESULTS. Clear cell RCCs exhibited significantly greater relative signal intensity compared with uninvolved renal cortex in the corticomedullary phase (mean, 2.9) than oncocytomas (-21.7, p = 0.001), papillary RCCs (-53.0, p < 0.001), and chromophobe RCCs (-21.0, p < 0.001). Relative signal intensity in the corticomedullary phase differentiated clear cell RCCs from oncocytomas with an AUC of 0.90 and with an accuracy of 84% (32/38), sensitivity of 90% (27/30), and specificity of 63% (5/8) after controlling for lesion size, patient age, and patient sex. Relative corticomedullary signal intensity differentiated clear cell RCCs from oncocytomas and other RCC subtypes with an AUC of 0.93 and with an accuracy of 90% (53/59), sensitivity of 90% (27/30), and specificity of 90% (26/29) after controlling for lesion size, patient age, and patient sex. CONCLUSION. Multiphasic MRI enhancement may assist in differentiating clear cell RCC from oncocytomas and other RCC subtypes, if validated in prospective studies.

Original languageEnglish (US)
Pages (from-to)812-819
Number of pages8
JournalAmerican Journal of Roentgenology
Volume208
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Oxyphilic Adenoma
Renal Cell Carcinoma
Area Under Curve
ROC Curve
Logistic Models
Regression Analysis
Clear-cell metastatic renal cell carcinoma
Prospective Studies
Kidney

Keywords

  • MRI
  • Multiphasic
  • Oncocytoma
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Performance of relative enhancement on multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) from Papillary and Chromophobe RCC subtypes and oncocytoma. / Young, Jonathan R; Coy, Heidi; Kim, Hyun J.; Douek, Michael; Lo, Pechin; Pantuck, Allan J.; Raman, Steven S.

In: American Journal of Roentgenology, Vol. 208, No. 4, 01.04.2017, p. 812-819.

Research output: Contribution to journalArticle

@article{dbedfe747f304435b312ef6b34a22487,
title = "Performance of relative enhancement on multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) from Papillary and Chromophobe RCC subtypes and oncocytoma",
abstract = "OBJECTIVE. The objective of our study was to investigate the performance of relative enhancement on multiphasic MRI to differentiate clear cell renal cell carcinoma (RCC) from other RCC subtypes (papillary and chromophobe) and oncocytoma. MATERIALS AND METHODS. For this study, we derived a cohort of 34 clear cell RCCs, nine oncocytomas, 12 papillary RCCs, and 10 chromophobe RCCs with a preoperative multiphasic dynamic contrast-enhanced MRI study with up to four phases (i.e., unenhanced, corticomedullary, nephrographic, excretory) from 2005 to 2016. These groups were evaluated for multiphasic enhancement and were compared using Kruskal-Wallis and Mann-Whitney tests. ROC curves were constructed and logistic regression analyses were performed to evaluate the performance of multiphasic enhancement in differentiating clear cell RCCs from the other three groups. RESULTS. Clear cell RCCs exhibited significantly greater relative signal intensity compared with uninvolved renal cortex in the corticomedullary phase (mean, 2.9) than oncocytomas (-21.7, p = 0.001), papillary RCCs (-53.0, p < 0.001), and chromophobe RCCs (-21.0, p < 0.001). Relative signal intensity in the corticomedullary phase differentiated clear cell RCCs from oncocytomas with an AUC of 0.90 and with an accuracy of 84{\%} (32/38), sensitivity of 90{\%} (27/30), and specificity of 63{\%} (5/8) after controlling for lesion size, patient age, and patient sex. Relative corticomedullary signal intensity differentiated clear cell RCCs from oncocytomas and other RCC subtypes with an AUC of 0.93 and with an accuracy of 90{\%} (53/59), sensitivity of 90{\%} (27/30), and specificity of 90{\%} (26/29) after controlling for lesion size, patient age, and patient sex. CONCLUSION. Multiphasic MRI enhancement may assist in differentiating clear cell RCC from oncocytomas and other RCC subtypes, if validated in prospective studies.",
keywords = "MRI, Multiphasic, Oncocytoma, Renal cell carcinoma",
author = "Young, {Jonathan R} and Heidi Coy and Kim, {Hyun J.} and Michael Douek and Pechin Lo and Pantuck, {Allan J.} and Raman, {Steven S.}",
year = "2017",
month = "4",
day = "1",
doi = "10.2214/AJR.16.17152",
language = "English (US)",
volume = "208",
pages = "812--819",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "4",

}

TY - JOUR

T1 - Performance of relative enhancement on multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) from Papillary and Chromophobe RCC subtypes and oncocytoma

AU - Young, Jonathan R

AU - Coy, Heidi

AU - Kim, Hyun J.

AU - Douek, Michael

AU - Lo, Pechin

AU - Pantuck, Allan J.

AU - Raman, Steven S.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - OBJECTIVE. The objective of our study was to investigate the performance of relative enhancement on multiphasic MRI to differentiate clear cell renal cell carcinoma (RCC) from other RCC subtypes (papillary and chromophobe) and oncocytoma. MATERIALS AND METHODS. For this study, we derived a cohort of 34 clear cell RCCs, nine oncocytomas, 12 papillary RCCs, and 10 chromophobe RCCs with a preoperative multiphasic dynamic contrast-enhanced MRI study with up to four phases (i.e., unenhanced, corticomedullary, nephrographic, excretory) from 2005 to 2016. These groups were evaluated for multiphasic enhancement and were compared using Kruskal-Wallis and Mann-Whitney tests. ROC curves were constructed and logistic regression analyses were performed to evaluate the performance of multiphasic enhancement in differentiating clear cell RCCs from the other three groups. RESULTS. Clear cell RCCs exhibited significantly greater relative signal intensity compared with uninvolved renal cortex in the corticomedullary phase (mean, 2.9) than oncocytomas (-21.7, p = 0.001), papillary RCCs (-53.0, p < 0.001), and chromophobe RCCs (-21.0, p < 0.001). Relative signal intensity in the corticomedullary phase differentiated clear cell RCCs from oncocytomas with an AUC of 0.90 and with an accuracy of 84% (32/38), sensitivity of 90% (27/30), and specificity of 63% (5/8) after controlling for lesion size, patient age, and patient sex. Relative corticomedullary signal intensity differentiated clear cell RCCs from oncocytomas and other RCC subtypes with an AUC of 0.93 and with an accuracy of 90% (53/59), sensitivity of 90% (27/30), and specificity of 90% (26/29) after controlling for lesion size, patient age, and patient sex. CONCLUSION. Multiphasic MRI enhancement may assist in differentiating clear cell RCC from oncocytomas and other RCC subtypes, if validated in prospective studies.

AB - OBJECTIVE. The objective of our study was to investigate the performance of relative enhancement on multiphasic MRI to differentiate clear cell renal cell carcinoma (RCC) from other RCC subtypes (papillary and chromophobe) and oncocytoma. MATERIALS AND METHODS. For this study, we derived a cohort of 34 clear cell RCCs, nine oncocytomas, 12 papillary RCCs, and 10 chromophobe RCCs with a preoperative multiphasic dynamic contrast-enhanced MRI study with up to four phases (i.e., unenhanced, corticomedullary, nephrographic, excretory) from 2005 to 2016. These groups were evaluated for multiphasic enhancement and were compared using Kruskal-Wallis and Mann-Whitney tests. ROC curves were constructed and logistic regression analyses were performed to evaluate the performance of multiphasic enhancement in differentiating clear cell RCCs from the other three groups. RESULTS. Clear cell RCCs exhibited significantly greater relative signal intensity compared with uninvolved renal cortex in the corticomedullary phase (mean, 2.9) than oncocytomas (-21.7, p = 0.001), papillary RCCs (-53.0, p < 0.001), and chromophobe RCCs (-21.0, p < 0.001). Relative signal intensity in the corticomedullary phase differentiated clear cell RCCs from oncocytomas with an AUC of 0.90 and with an accuracy of 84% (32/38), sensitivity of 90% (27/30), and specificity of 63% (5/8) after controlling for lesion size, patient age, and patient sex. Relative corticomedullary signal intensity differentiated clear cell RCCs from oncocytomas and other RCC subtypes with an AUC of 0.93 and with an accuracy of 90% (53/59), sensitivity of 90% (27/30), and specificity of 90% (26/29) after controlling for lesion size, patient age, and patient sex. CONCLUSION. Multiphasic MRI enhancement may assist in differentiating clear cell RCC from oncocytomas and other RCC subtypes, if validated in prospective studies.

KW - MRI

KW - Multiphasic

KW - Oncocytoma

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85016514155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016514155&partnerID=8YFLogxK

U2 - 10.2214/AJR.16.17152

DO - 10.2214/AJR.16.17152

M3 - Article

C2 - 28125273

AN - SCOPUS:85016514155

VL - 208

SP - 812

EP - 819

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 4

ER -